Business Wire

Ascom Myco smarttelefon for helsesektoren er nå kompatibel med Ekahau RTLS

Del

Ascom Wireless Solutions og Ekahau, en ledende leverandør av sanntidslokaliseringssystemer (RTLS), kunngjør at Ascom Myco smarttelefon nå er kompatibel med Ekahau RTLS. Ascom Myco er markedets første smarttelefon spesialdesignet til helsesektoren. Det er et avansert informasjonssystem som gir fleksibilitet, holdbarhet og praktisk nytte i et og samme håndsett. Ascom Myco er designet spesielt for pleiepersonale, og brukerne kan nå få glede av Ekahau RTLS-lokaliseringsfunksjonalitet.

RFID-over-Wi-Fi™ er en proprietær teknologi fra Ekahau som sender data om hvor personer og utstyr befinner seg. Dataene kan gi f.eks. sykehus viktig informasjon i sanntid. Ekahau RTLS-løsninger er alltid operative og benyttes av noen av verdens største helseinstitusjoner – hvorav mange også benytter Ascom-løsninger. Lokalitseringsdata kan gi besparelser og forbedre pleien. "Vårt felles mål er å hjelpe pleiepersonale med å bli mer effektive, og i den forstand fungerer Ekahau og Ascoms Wi-Fi-baserte løsninger meget godt sammen," sier Ekahaus administrerende direktør, Michel Wendell. "IoE ("The Internet of Everything") er over oss, og nå kan sykepleiere over alt føle større trygghet med én enhet som er aktivert for lokalisering".

For Henrik Sandberg, Alliances Manager hos Ascom Wireless Solutions, stadfester kompatibiliteten med Ekahau RTLS Ascom Mycos evne til å støtte en lang rekke applikasjoner og funksjoner til helsesektoren. "Denne brede formen for støtte bidrar til at Ascom Myco er pleiepersonalets foretrukne løsning", sier Sandberg. Alarmer, anrop, pasientdata og nå personalarmer med RTLS, nesten alle de tidskritiske data som pleierne har bruk for, er nå tilgjengelig i ett håndsett som er spesialdesignet til helesektoren."

For mer informasjon om Ascom Myco, besøk www.ascommyco.com For mer informasjon om Ekahau RTLS, besøk www.ekahau.com/rtls.com Eksisterende Ascom-brukere kan oppgradere til Ascom Myco og aktivere Ekahau RTLS ved å kontakte deres Ascom-forhandler eller Ekahau direkte på 866-4-EKAHAU.

For mer informasjon, besøk www.ascom.com/ws

OM ASCOM WIRELESS SOLUTIONS

Ascom Wireless Solutions (www.ascom.com/ws) er en ledende leverandør av innovative kommunikasjonsløsninger for integrerte arbeidsprosesser for segmenter som sykehus, eldreomsorg, samt på andre områder der virksomhetskritisk kommunikasjon er viktig. Ca. 100 000 systemer er installert globalt. Selskapet tilbyr et bredt utvalg profesjonelle telefoni- og meldingssystemer, og genererer verdi for kundene ved å støtte og optimere deres virksomhetskritiske prosesser. Løsningene er basert på mobil, VoWiFi, IP-DECT, pasientsignal og personsøkerteknologi som integreres på en smart måte i eksisterende virksomhetssystemer. Selskapet har datterselskaper i 13 land og 1200 ansatte globalt. Firmaet ble grunnlagt i Göteborg i 1955 og er en del av Ascom Group som er børsnotert på Swiss Stock Exchange (ASCN:SIX).

OM EKAHAU

Ekahau er en ledende leverandør av Wi-Fi-basert RTLS og planløsninger for Wi-Fi-nettverksoptimalisering. Med innovative produkter og patentert teknologi leverer Ekahau overlegne løsninger til organisasjoner som ønsker bedre business intelligence og driftssikkerhet, for å lykkes bedre med deres virksomhet. Fra kapitalforvaltning og medarbeidersikkerhet til temperaturovervåking, gir Ekahau RTLS lokaliseringsklarhet til hele helseinstitusjonen. Ekahaus løsninger brukes av Fortune 500-selskaper og mer enn 300 sykehus, samt en rekke internasjonale selskaper innenfor sektorer som produksjon, butikk, industri, offentlighet og det militære. Ekahaus partnere inkluderer utviklere av trådløse programvarer, ledende systemintegratorer og internasjonale OEM-partnere, som utvikler og markedsfører trådløse bedriftsapplikasjoner.

Contact information

Ascom Wireless Solutions
Henrik Sandberg
Tlf.: +46 703 533 578
E-postadresse: Henrik.Sandberg@ascom.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00Pressemelding

Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im

CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00Pressemelding

Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates

Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26Pressemelding

Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a

General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05Pressemelding

General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges

Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03Pressemelding

Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o

Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00Pressemelding

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and